Abstract
Background: Nabiximols (Sativex®) is a cannabis-based oromucosal spray, with each spray containing 2.7 mg delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD). It is licensed for the treatment for spasticity in patients with MS (pwMS) but not other neurological conditions, and evidence for its efficacy in the latter is limited. We describe our experience using Nabiximols for spasticity management in the west of Scotland within a neurorehabilitation setting.
Methods: A two-centre retrospective review of Nabiximols trial outcomes from 2019 and 2023 was performed for both patients with MS (pwMS) and non-MS diagnoses (pwNMS).
Results: Fifty-five pwMS (86%) had a successful Nabiximols trial, with significant improvements in Numerical Rating Scales (NRS) for stiffness at 5.5 ± 2.4 (95% CI: 1.58–3.46, p<0.001), spasms at 4.8 ± 2.5 (95% CI: 1.71– 3.61, p<0.001) and pain at 3.7 ± 2.8 (95% Confidence Interval [CI]: 0.56–2.63, p=0.04). Seven pwNMS (78%) had a successful Nabiximols trial (3 Hereditary Spastic Paraparesis [HSP], 3 Cerebral Palsy and 1 Stroke).
Conclusion: The Nabiximols response rate in our cohort of pwMS is slightly higher at 86% compared to similar studies, likely as a result of patients presenting at a more advanced stage of MS within a specialist spasticity service. Nabiximols is also shown to be effective in HSP and other non-MS conditions in reducing spasticity-related symptoms and improving function.
Introduction
Spasticity is defined as a sensory-motor disorder characterised by intermittent or sustained involuntary muscular contraction, as a result of an upper motor neuron (UMN) lesion [1]. Spasticity presents in a spectrum of severity, and is a common manifestation of the UMN syndrome. Spasticity can be beneficial in some patients to maintain transfers and ambulation, especially for those with significant underlying weakness, however for many it is troublesome. Finding a balance between symptomatic control of spasticity and maintenance of functional independence in a goal-oriented approach can be a challenge [2].
Knowledge of the full range of treatment modalities for spasticity is crucial in striking this balance. This typically starts with conservative management of trigger factors and physiotherapy, with treatment escalated to pharmacological options including oral agents, focal interventions, and more invasive modalities such as intrathecal therapies and surgery, depending on clinical presentation and symptom severity [2].
Pharmaceutical cannabinoids, especially Nabiximols, have been reported to be an effective oral add-on treatment option for intractable spasticity in patients with multiple sclerosis (pwMS), based on the presumed effect on the endogenous cannabinoid system although the exact mechanism is not completely understood [3,4]. In the UK, this is typically offered in pwMS only after first-line oral pharmacological options have not been successful [5,6].
The use of Nabiximols in pwMS has been of recent interest in Scotland, since its acceptance by the Scottish Medicines Consortium (SMC), the Health Technology Assessment body in Scotland, in September 2022 for people that have not responded well to first line options as oral medications (Baclofen, Gabapentin, Diazepam, Tizanidine and/or Dantrolene) or focal management with botulinum toxin. The effectiveness and tolerability of Nabiximols in patients with MS is well-established [3,4], with UK guidance recommending the use of Nabiximols in pwMS with intractable spasticity who experience at least a 20% reduction in spasticity-related symptoms following a 4-week trial [6].
However, the evidence for Nabiximols in the management of spasticity in non-MS conditions is limited, although emerging. Recent small randomised-controlled trials in patients with motor neuron disease and stroke have reported Nabiximols improving spasticity symptoms compared to placebo [7,8]. The reported benefits of cannabinoid in spasticity management for non-MS conditions should not be surprising as the pathophysiological processes underpinning the clinical presentation of spasticity is the same.
Other treatments that could be considered for people with intractable spasticity are intrathecal baclofen, which has clinical evidence as an effective alternative [9].
We describe our experience through a retrospective service evaluation of using Nabiximols in the management of intractable spasticity in both pwMS and other neurological conditions within a specialist spasticity management setting in the West of Scotland.
Methods
Participants and settings
PwMS and non-MS diagnoses (pwNMS) considered for Nabiximols at two separate neurorehabilitation services in the West of Scotland between 2019 and 2023 were included in this retrospective cohort study. For a patient to be considered for Nabiximols, there is a requirement to have been trialled on first-line oral pharmacological options for spasticity including Baclofen, Gabapentinoids and Tizanidine without success at maximum dose or being tolerated at any dose.
Trial and prescription
Prior to Scottish Medicines Consortium (SMC) acceptance, pwMS considered for Nabiximols in Scotland required the treatment to be approved on a case-by-case basis through an Individual Patient Treatment Request process. For pwNMS, a similar application process was followed through local policies on unlicensed medicine or off-label requests. Once approved, a 4-week trial of Nabiximols was offered as outlined in the National Institute for Health and Care Excellence (NICE) guidelines [6].
Patient-reported outcomes
Formal patient-reported outcomes collected prospectively as part of the 4-week trial include a numerical rating scale (NRS) on stiffness, spasms and pain collected at weeks 0 (pre-trial) and 4 (post-trial). Informal outcomes documented include medication burden and functional change.
Statistical analysis
Patients were classified by diagnoses (pwMS and pwNMS). Wilcoxon signed-rank test was used to compare pre-trial and post-trial NRS scores, and measure effect size. Shapiro-Wilk test was used to test for normality. All data was analysed using R-4.3.2 and graphs prepared with GraphPad Prism 7. P < 0.05 was considered statistically significant.
Ethical approval
Caldicott guardian approvals were granted for both services.
Results
Seventy-five patients were trialled on Nabiximols during the study period with 62 (83%; 55 pwMS, 7 pwNMS) reporting it to be successful, represented by a 20% reduction in their symptom(s). Two pwMS were excluded from further analysis due to missing data and the remaining results are based on 73 patients (mean age 56.2 ± 10.4 years; range 28-88 years).
PwMS (n=64)
Of the 64 pwMS, 6 (9%) had a diagnosis of relapsing-remitting MS, 7 (11%) primary progressive MS, and 51 (80%) secondary progressive MS.
Fifty-five (86%) had a successful Nabiximols trial (89% women; mean age 55.6 ± 8.5 years, mean Expanded Disability Status Scale (EDSS) 7.3 ± 0.8; mean time since diagnosis 18.9 ± 9.3 years). On average the participants used 7.8 ± 2.8 sprays during their trial. The reasons for unsuccessful trials were side effects of increased weakness (n=2) and inadequate response (n=7). Fifty-three (80%) continued to use the medication at 6 month follow up, with main reason for stopping being the development of intolerable side effects (n=2).
Statistical analysis was performed with the 60 pwMS that had complete pre and post NRS data regardless if it was considered successful or not. Median post-trial NRS scores were significantly lower than pre-trial scores (pain from 6 to 3 (p < 0.01), stiffness from 8 to 5.25 (p < 0.01), and spasms from 8 to 4 (p < 0.01). (Figure 1). Effect size for pain was moderate (r=0.5) and large for stiffness and spasm (r=0.76).

PwNMS (n=9)
Of the 9 pwNMS, 3 (33%) had a diagnosis of Hereditary Spastic Paraparesis (HSP) (median age of 55 years (range 48-72 years)); 4 (45%) Cerebral Palsy (CP) (median age 42 years (range 28-56 years)); and 2 (22%) had other diagnoses (median age 47 years (range 30-63 years)).
Seven (78%) had a successful Nabiximols trial (3 HSP, 3 CP, 1 stroke; 44% women; mean age 40.3 ± 13.3 years, mean time since diagnosis 12.5 ± 11.7 years) and all continued to use the medication at 6 months follow up. The successful participants used on average 6.8 ± 3.6 sprays during their trial. The reasons for unsuccessful trials were due to systemic intolerance (n=1) and inadequate response (n=1). Mean pre-trial NRS scores for pain were 6.2 ± 3.2, stiffness 9.3 ± 1.2 and spasms 5.0 ± 3.6. Mean post-trial NRS scores were lower for pain 4.7 ± 2.5, stiffness 6.0 ± 1.4 and spasms 0.7 ± 1.2. Statistical analysis was not attempted due to low sample size.
In addition, pwNMS who had a successful Nabiximols trial also reported improvements to other areas, including ease of activities of daily living (n=3), ease of donning footwear (n=1) and ease of transfers (n=1). Several patients were also able to reduce the need for further focal treatment with Botulinum toxin (n=4) and oral medications (n=4), and reported reduced drowsiness as a result (n=2). There was no similar data collated for pwMS who had a successful trial.
Conclusion
The initial response rate of trialling Nabiximols with a ≥20% improvement in spasticity symptoms at 4 weeks in our cohort of pwMS is 86%, with 83% still reporting benefits at 6 months. This is higher than the 48-81% reported in other studies [10-12], which is likely in part related to patient selection encountered within a neurorehabilitation setting. The patients encountered and put forward for the Nabiximols trial were predominantly patients with progressive MS (90%) with a longer time from initial diagnosis (mean 19 years) and higher EDSS (mean 7.3) compared to existing studies. The SAVANT trial of 191 pwMS reported that 59% of participants had progressive MS, with a mean duration from initial diagnosis at 14 years and mean EDSS of 5.9 [11]. It may be the case that for patients with more advanced MS with a higher spasticity symptom burden, they are more likely respond to generalised treatment. An alternative to this medication is to perform an intrathecal baclofen trial [9].
Moreover, our neurorehabilitation services also manage spasticity within a specialist spasticity service, offering a range of treatment options depending on the pattern of spasticity presentation (e.g. focal Botulinum toxin injections, nerve blocks for focal spasticity including intrathecal baclofen delivery). Prior to the SMC acceptance, our pwMS cohort historically have only been offered Nabiximols if they have a more severe or complex spasticity symptom burden that have not responded to more specialist interventions. This clinical practice has changed since the SMC acceptance in September 2022, making Nabiximols more readily available at an earlier stage. Further considerations for intrathecal therapy are still available for all this population if required.
We found that in pwMS the average dose required to give benefit was 7.8 ± 2.8, whilst in pwNMS, this was 6.8 ± 3.6 sprays. To our knowledge, this is also the first reported successful use of Nabiximols in the management of spasticity in patients with hereditary spastic paraparesis, and on average these patients required a dose of 8.7 ± 1.5 sprays. In the small sample of pwNMS trialled on Nabiximols, this has been shown to be beneficial in reducing spasticity symptoms when most other interventions were unsuccessful. Nabiximols should be considered as an unlicensed treatment option for pwNMS if other treatment modalities have been exhausted, although more research is required in this area.
The benefit of Nabiximols is not just limited to symptomatic improvement of spasticity symptoms. There are anecdotal reports from our patients suggesting benefits in function and quality of life (QoL). This is supported by other recent studies that have reported improvements in specific functional outcomes such as walking performance [13], ADLs [14], and even driving fitness [15], from the use of Nabiximols in pwMS. As part of routine clinical practice, there will be a need to assess the impact of Nabiximols on function and QoL more formally. The use of goal attainment scaling has been proposed to measure functional outcome in the use of Nabiximols [16], although its use may be problematic as the treatment benefit from Nabiximols on function is not always predictable prior to a trial.
|Sign up for ACNR email updates – the latest articles in your inbox |
The main limitations of this retrospective cohort study are its small sample size and selection bias as described, although this is specifically within the context of a specialist spasticity service within a neurorehabilitation setting. However, it continues to support the use of Nabiximols in both pwMS and pwNMS in routine clinical practice in the management of intractable spasticity.
References
- Burridge JH, Wood DE, Hermens HJ, et al. Theoretical and methodological considerations in the measurement of spasticity. Disabil Rehabil. 2005;27:69-80. https://doi.org/10.1080/09638280400014592
- Royal College of Physicians. Spasticity in adults: management using botulinum toxin. London, https://www.rcplondon.ac.uk/guidelines-policy/spasticity-adults-management-using-botulinum-toxin (2018).
- Nielsen S, Germanos R, Weier M, et al. The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews. Curr Neurol Neurosci Rep. 2018;18:8. https://doi.org/10.1007/s11910-018-0814-x
- Filippini G, Minozzi S, Borrelli F, et al. Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis. Cochrane database Syst Rev 2022; 5: CD013444.https://doi.org/10.1002/14651858.CD013444.pub2
- National Institute for Health and Care Excellence. Multiple sclerosis in adults: management. London, https://www.nice.org.uk/guidance/ng220 (2022).
- National Institute for Health and Care Excellence. Cannabis-based medicinal products. London, https://www.nice.org.uk/guidance/ng144 (2021).
- Riva N, Mora G, Sorarù G, et al. Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2019;18:155-164. https://doi.org/10.1016/S1474-4422(18)30406-X
- Marinelli L, Puce L, Mori L, et al. Cannabinoid Effect and Safety in Spasticity Following Stroke: A Double-Blind Randomized Placebo-Controlled Study. Front Neurol. 2022;13:892165. https://doi.org/10.3389/fneur.2022.892165
- Cozzi FM, Zuckerman D, Sacknovitz A, Gozum N, Syal A, Danisi F, Sukul V. (2024). Outcomes, complications, and dosing of intrathecal baclofen in the treatment of multiple sclerosis: a systematic review. Neurosurgical Focus. 2024;56(6), E14 https://doi.org/10.3171/2024.3.FOCUS2464
- Novotna A, Mares J, Ratcliffe S, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Nabiximols(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol. 2011;18:1122-1131. https://doi.org/10.1111/j.1468-1331.2010.03328.x
- Markovà J, Essner U, Akmaz B, et al. Nabiximols(®) as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial. Int J Neurosci. 2019;129:119-128. https://doi.org/10.1080/00207454.2018.1481066
- D’hooghe M, Willekens B, Delvaux V, et al. Nabiximols® (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience. BMC Neurol. 2021;21:227. https://doi.org/10.1186/s12883-021-02246-0
- De Blasiis P, Siani MF, Fullin A, et al. Short and long term effects of Nabiximols on balance and walking assessed by 3D-gait analysis in people with Multiple Sclerosis and spasticity. Mult Scler Relat Disord. 2021;51: 102805. https://doi.org/10.1016/j.msard.2021.102805
- Arroyo R, Vila C, Dechant KL. Impact of Nabiximols(®) on quality of life and activities of daily living in patients with multiple sclerosis spasticity. J Comp Eff Res. 2014;3:435-444. https://doi.org/10.2217/cer.14.30
- Freidel M, Tiel-Wilck K, Schreiber H, et al. Drug-resistant MS spasticity treatment with Nabiximols(®) add-on and driving ability. Acta Neurol Scand. 2015;131:9-16. https://doi.org/10.1111/ane.12287
- Paul F, Silván CV. Effect of nabiximols on Goal Attainment Scale scores in patients with treatment-resistant multiple sclerosis spasticity. Neurodegener Dis Manag. 2021;11:143-153. https://doi.org/10.2217/nmt-2020-0060

